Just weeks after sharing that it was planning cost cuts that would include layoffs, Prothena has announced a 63% workforce reduction. That reduction likely includes the 91 people the Dublin-headquartered biotech disclosed it was letting go in Brisbane, California, via a Worker Adjustment and Retraining Notification notice earlier this month.
All entries for: Prothena
June 23, 2025
Prothena - Dublin
Layoffs
Dublin, IE
51-200 employees
Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
May 27, 2025
Prothena - Bresbane
Layoffs
Bresbane, CA
51-200 employees
After its anti-amyloid antibody birtamimab missed its primary endpoint in the Phase III AFFIRM-AL trial, Prothena is evaluating business options that include an “expected substantial workforce reduction,” the company announced May 23. The biotech will provide more details regarding the strategic review in June. Prothena in May announced that it would no longer invest in the development of its anti-amyloid antibody birtamimab after it failed the Phase III AFFIRM-AL trial in patients with AL amyloidosis.
Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule